MeiraGTx scores $400M to boost commercialization push
MeiraGTx scores $400M to boost commercialization push (reported by Fierce Biotech)
MeiraGTx
London-based gene therapy company developing treatments for Parkinson's disease, radiation-induced xerostomia, and inherited retinal diseases, using proprietary Riboswitch gene regulation platform.
Company Info
Upcoming Milestones & Key Dates
2026-Q3
business
Oberland Capital $400M financing close expected
2026-Q4
clinical
Phase 3 Parkinson trial interim data read-out
Clinical Development Pipeline
AAV-GAD
Target: Glutamic acid decarboxylaseAAV-RNAP/S
Target: Aquaporin-1 / Salivary glandAAV-CNGA3
Target: CNGA3 geneRecent News
Oberland pours up to $400M into MeiraGTx eye gene therapies
Oberland pours up to $400M into MeiraGTx eye gene therapies (reported by BioPharma Dive)
Leadership Team
Alexandria Forbes
President and Chief Executive Officer
Richard Giroux
Chief Operating Officer
Stuart Naylor
Chief Development Officer